PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

New York, May 22, 2025 (GLOBE NEWSWIRE) -- PESG Research today announced the release of a report examining Silexion Therapeutics, an innovative biotechnology company developing unique RNA interference (RNAi) therapies targeting KRAS-driven cancers. The below report explores the company's disruptive technological approach, recent scientific milestones, and potential implications for cancer treatment strategies, in the fast growing precision oncology market. Executive Summary The precision oncology landscape ...